Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs ArcelorMittal SA — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while ArcelorMittal SA trades at $62.47 (market cap $47.37B). The key difference: ArcelorMittal SA is far larger — about 5.3× Kymera Therapeutics Inc. Common Stock's market cap, and ArcelorMittal SA pays a 0.95% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and ArcelorMittal SA for 36 Days on average.
| KYMR | MT | |
|---|---|---|
Market Cap | $8.87B | $47.37B |
Volume | 779,107 | 616,736 |
Sector | Health | Basic Materials |
52-Week High | $127.31 | $78.74 |
52-Week Low | $55.80 | $36.91 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $8.26B | $56.95B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ArcelorMittal (MT) trades at $62.49, down 0.73% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with declining revenue from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent Ukraine plant impairments and missile strikes create operational headwinds, while analyst consensus remains positive with a $74.33 price target representing 19% upside potential.
MT presents a value opportunity with attractive valuation multiples (P/S 0.77, P/B 0.87) and strong cash flow generation, but faces significant geopolitical risks and declining revenue trends. The company's strategic shift toward regional operations and shareholder returns supports long-term potential, though near-term volatility from European demand fluctuations and Ukraine impairments requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
